专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20120322836A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR STABILIZING THE SAME 审中-公开
标题翻译：药物组合物及其稳定化方法
公开(公告)号：US20120322836A1
公开(公告)日：2012-12-20
申请号：US13600083
申请日：2012-08-30
申请人： Gopal Krishna , Rajeshwar Motheram , Min Ding
发明人： Gopal Krishna , Rajeshwar Motheram , Min Ding
IPC分类号： A61K31/4418 , A61P9/12 , C07D213/80
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/10 , A61K31/435 , A61K31/4418 , A61K2300/00
摘要： Pharmaceutical compositions, and a method of stabilizing pharmaceutical compositions having clevidipine, or any pharmaceutically acceptable salt thereof, as the active ingredient is described. The method includes the slowing down or inhibiting of the oxidation pathway of clevidipine. This can be accomplished by reducing the amount the pharmaceutical composition is exposed to oxygen and/or light during the manufacturing and storing processes. According to this method, oxygen must be removed or replaced, or light must be sufficiently blocked such that light energy cannot reach the active ingredient of the composition, or is reduced to a level that the light-induced oxidation reaction converting clevidipine to H324/78 is minimized, such that the total detectable level of H324/78 in a given composition sample does not exceed about 0.2% on a weight-by-weight basis, or the ratio of clevidipine to H324/78 is equal to or greater than about 450 to 1 on a weight-to-weight basis.
摘要翻译：描述了药物组合物和稳定具有氯维地平的药物组合物或其任何药学上可接受的盐作为活性成分的方法。该方法包括减缓或抑制氯维地平的氧化途径。这可以通过在制造和储存过程中减少药物组合物暴露于氧和/或光的量来实现。根据该方法，必须除去或更换氧气，或者必须充分阻挡光，使得光能不能达到组合物的活性成分，或者降低到光诱导的氧化反应将氯维地平转化为H324 / 78 被最小化，使得给定组合物样品中H324 / 78的总可检测水平以重量计不超过约0.2％，或者氯维地平与H324 / 78的比例等于或大于约450 至1，以重量为基准。

12. 发明申请

US20120322835A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME 审中-公开
标题翻译：药物组合物及其生产低劣化浓度的方法
公开(公告)号：US20120322835A1
公开(公告)日：2012-12-20
申请号：US13600056
申请日：2012-08-30
申请人： Rajeshwar Motheram , Gopal Krishna , Min Ding , Keith Flood , Kornepati Ramakrishna
发明人： Rajeshwar Motheram , Gopal Krishna , Min Ding , Keith Flood , Kornepati Ramakrishna
IPC分类号： A61K31/4418 , C07D213/80 , G01N30/00 , A61P9/12
CPC分类号： A61K31/4422 , A61K31/519 , G01N30/02
摘要： A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.
摘要翻译：描述了具有氯维地平作为活性成分的组合物。组合物包括氯维西肽作为活性成分，杂质H168 / 79的量不大于约1.5％，或者氯维地平与H168 / 79之间的比例等于或大于60比1。

13. 发明申请

US20110123627A1 HIGH DENSITY COMPOSITIONS CONTAINING POSACONAZOLE AND FORMULATIONS COMPRISING THE SAME 审中-公开
标题翻译：含有噻吗唑的高密度组合物和包含它们的制剂
公开(公告)号：US20110123627A1
公开(公告)日：2011-05-26
申请号：US12999547
申请日：2009-04-15
申请人： Larry Yun Fang , David Harris , Gopal Krishna , Allen E. Moton, JR. , Russell C. Prestipino , Marc Steinman , Jiansheng Wan , Hetty Anne Waskin
发明人： Larry Yun Fang , David Harris , Gopal Krishna , Allen E. Moton, JR. , Russell C. Prestipino , Marc Steinman , Jiansheng Wan , Hetty Anne Waskin
IPC分类号： A61K31/496 , A61K9/14 , A61P31/10
CPC分类号： A61K47/38 , A61K9/14 , A61K9/1652 , A61K31/496
摘要： The present application provides novel compositions comprising posaconazole and a polymer wherein the composition has a glass transition temperature (Tg) of less than about 1100 C. The application also describes compositions comprising posaconazole and a polymer having a bulk density of greater than about 0.4 mg/mL. The application also describes compositions comprising posaconazole and a polymer which provide an exposure (AUCtf) of at least about 10,000 ng·hr/mL when administered to a patient in a fasted state. The application also describes a novel process for preparing these compositions. The preff erred polymer is HPMCAS. Preferably the composition is an extruded material.
摘要翻译：本申请提供了包含泊沙康唑和聚合物的新型组合物，其中组合物的玻璃化转变温度（Tg）小于约1100℃。本申请还描述了包含泊沙康唑和堆积密度大于约0.4mg / mL。本申请还描述了当以禁食状态给予患者时，包含泊沙康唑和提供至少约10,000ng·hr / mL的暴露（AUCtf）的聚合物的组合物。本申请还描述了一种制备这些组合物的新方法。优先聚合物是HPMCAS。优选地，组合物是挤出材料。

14. 发明申请

US20060009469A1 Particulate-stabilized injectable pharmacutical compositions of posaconazole 审中-公开
标题翻译：泊沙康唑的颗粒稳定的可注射药物组合物
公开(公告)号：US20060009469A1
公开(公告)日：2006-01-12
申请号：US11140294
申请日：2005-05-27
申请人： Leonore Witchey-Lakshmanan , Sydney Ugwu , Varda Sandweiss , Catherine Hardalo , Roberta Hare , Gopal Krishna , Zaiqi Wang , Marco Taglietto
发明人： Leonore Witchey-Lakshmanan , Sydney Ugwu , Varda Sandweiss , Catherine Hardalo , Roberta Hare , Gopal Krishna , Zaiqi Wang , Marco Taglietto
IPC分类号： A61K31/496
CPC分类号： A61K9/0019 , A61K31/137 , A61K31/496 , A61K31/513 , A61K31/7048 , A61K45/06 , A61K47/24 , A61K47/26 , Y02A50/409 , Y02A50/414 , A61K2300/00
摘要： The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient posaconazole in an injectable suspension that is stable when subjected to terminal steam sterilization.
摘要翻译：本发明提供了可用于治疗感染的制剂，特别是在经受终端蒸汽灭菌时稳定的可注射悬浮液中包含活性药物成分泊沙康唑的制剂。

15. 发明授权

US06950434B1 Arrangement for searching packet policies using multi-key hash searches in a network switch 有权
标题翻译：在网络交换机中使用多键哈希搜索搜索分组策略的布置
公开(公告)号：US06950434B1
公开(公告)日：2005-09-27
申请号：US09496212
申请日：2000-02-01
申请人： Somnath Viswanath , Gopal Krishna
发明人： Somnath Viswanath , Gopal Krishna
IPC分类号： H04L12/28 , H04L12/56
CPC分类号： H04L49/3009 , H04L49/351 , H04L49/602
摘要： A network switch, configured for performing layer 2 and layer 3 switching in an Ethernet (IEEE 802.3) network without blocking of incoming data packets, includes network switch ports, each including a flow module configured for generating a packet signature based on layer 3 information within a received data packet. The flow module generates first and second hash keys according to a prescribed hashing function upon obtaining first and second portions of layer 3 information. The flow module combines the first and second hash keys to form the packet signature, and searches an on-chip signature table that indexes addresses of layer 3 switching entries by entry signatures, where the entry signatures are generated using the same prescribed hashing function on the first and second layer 3 portions of the layer 3 switching entries.
摘要翻译：配置用于在以太网（IEEE 802.3）网络中执行层2和层3切换而不阻塞传入数据分组的网络交换机包括网络交换机端口，每个网络交换机端口包括被配置用于基于第3层内的信息生成分组签名的流模块接收到的数据包。流模块在获得第三层信息的第一和第二部分时，根据规定的散列函数生成第一和第二散列密钥。流模块组合第一和第二散列密钥以形成分组签名，并且搜索片上签名表，其通过条目签名索引第3层交换条目的地址，其中使用相同的规定散列函数生成条目签名层3的第一和第二层3部分切换条目。

16. 发明授权

US06760341B1 Segmention of buffer memories for shared frame data storage among multiple network switch modules 失效
标题翻译：在多个网络交换机模块之间分割用于共享帧数据的缓冲存储器
公开(公告)号：US06760341B1
公开(公告)日：2004-07-06
申请号：US09512591
申请日：2000-02-24
申请人： Bahadir Erimli , Gopal Krishna
发明人： Bahadir Erimli , Gopal Krishna
IPC分类号： H04L1228
CPC分类号： H04L49/103 , H04L49/15 , H04L49/351 , H04L49/90 , H04L49/9057
摘要： A network switching system having a plurality of multiport switch modules and respective connected buffer memory devices assigns in each of the buffer memory devices a memory segment for storage of frame data from a corresponding one of the switch modules. Each memory device is divided into memory segments, also referred to as memory regions, wherein each memory segment is configured for storing frame data from a corresponding one of the switch modules. Hence, each switch module is configured for writing frame data, for a data frame received on one of the corresponding switch ports, into the corresponding assigned memory segment of each of the buffer memory devices. Any one of the switch modules can access any location of the buffer memory devices, enabling any one switch module to retrieve frame data from the buffer memory devices that was stored by another one of the switch modules. In addition, the assignment of memory segments enables a switch module having accessed frame data from the buffer memory to determine the switch module that originally stored the frame data based on the location of the stored frame data within one of the memory segments, simplifying buffer memory resource management.
摘要翻译：具有多个多端口交换模块和相应连接的缓冲存储器设备的网络交换系统在每个缓冲存储器设备中分配用于从对应的一个交换机模块存储帧数据的存储器段。每个存储器件被分成存储器段，也称为存储器区域，其中每个存储器段被配置用于存储来自相应的一个开关模块的帧数据。因此，每个开关模块被配置为将对于在相应的开关端口之一接收的数据帧写入帧数据到每个缓冲存储器件的相应的分配的存储器段中。任何一个交换机模块可以访问缓冲存储器设备的任何位置，使得任何一个交换机模块能够从由另一个交换机模块存储的缓冲存储器设备中检索帧数据。此外，存储器段的分配使得具有来自缓冲存储器的已访问帧数据的交换机模块基于存储在其中一个存储器段中的存储的帧数据的位置来确定原始存储帧数据的交换模块，从而简化缓冲存储器资源管理。

17. 发明申请

US20100113534A1 Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same 审中-公开
标题翻译：用于生产低杂质浓度的药物组合物和方法
公开(公告)号：US20100113534A1
公开(公告)日：2010-05-06
申请号：US12511631
申请日：2009-07-29
申请人： Rajeshwar Motheram , Gopal Krishna , Min Ding , Keith Flood , Kornepati Ramakrishna
发明人： Rajeshwar Motheram , Gopal Krishna , Min Ding , Keith Flood , Kornepati Ramakrishna
IPC分类号： A61K31/4418 , G01N30/02
CPC分类号： A61K31/4422 , A61K31/519 , G01N30/02
摘要： A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.
摘要翻译：描述了具有氯维地平作为活性成分的组合物。组合物包括氯维西肽作为活性成分，杂质H168 / 79的量不大于约1.5％，或者氯维地平与H168 / 79之间的比例等于或大于60比1。

18. 发明申请

US20100105743A1 Pharmaceutical compositions and methods for stabilizing the same 审中-公开
标题翻译：药物组合物及其稳定方法
公开(公告)号：US20100105743A1
公开(公告)日：2010-04-29
申请号：US12462147
申请日：2009-07-30
申请人： Gopal Krishna , Rajeshwar Motheram , Min Ding
发明人： Gopal Krishna , Rajeshwar Motheram , Min Ding
IPC分类号： A61K31/44 , A61P9/12
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/10 , A61K31/435 , A61K31/4418 , A61K2300/00
摘要： Pharmaceutical compositions, and a method of stabilizing pharmaceutical compositions having clevidipine, or any pharmaceutically acceptable salt thereof, as the active ingredient is described. The method includes the slowing down or inhibiting of the oxidation pathway of clevidipine. This can be accomplished by reducing the amount the pharmaceutical composition is exposed to oxygen and/or light during the manufacturing and storing processes. According to this method, oxygen must be removed or replaced, or light must be sufficiently blocked such that light energy cannot reach the active ingredient of the composition, or is reduced to a level that the light-induced oxidation reaction converting clevidipine to H324/78 is minimized, such that the total detectable level of H324/78 in a given composition sample does not exceed about 0.2% on a weight-by-weight basis, or the ratio of clevidipine to H324/78 is equal to or greater than about 450 to 1 on a weight-to-weight basis.
摘要翻译：描述了药物组合物和稳定具有氯维地平的药物组合物或其任何药学上可接受的盐作为活性成分的方法。该方法包括减缓或抑制氯维地平的氧化途径。这可以通过在制造和储存过程中减少药物组合物暴露于氧和/或光的量来实现。根据该方法，必须除去或更换氧气，或者必须充分阻挡光，使得光能不能达到组合物的活性成分，或者降低到光诱导的氧化反应将氯维地平转化为H324 / 78 被最小化，使得给定组合物样品中H324 / 78的总可检测水平以重量计不超过约0.2％，或者氯维地平与H324 / 78的比例等于或大于约450 至1，以重量为基准。

19. 发明授权

US07598343B1 Pharmaceutical formulations of bivalirudin and processes of making the same 有权
标题翻译：比伐卢定的药物制剂及其制备方法
公开(公告)号：US07598343B1
公开(公告)日：2009-10-06
申请号：US12180551
申请日：2008-07-27
申请人： Gopal Krishna , Gary Musso
发明人： Gopal Krishna , Gary Musso
IPC分类号： A61K38/55 , C07K7/08 , C07K7/64 , C07K1/00 , C07K1/04 , C07K14/00
CPC分类号： C07K7/08 , A61K9/0019 , A61K38/58 , A61K47/02 , A61K47/26
摘要： Pharmaceutical batch(es) or pharmaceutical formulation(s) comprising bivalirudin as the active ingredient, and a method of preparing the pharmaceutical batch(es) or pharmaceutical formulation(s). The pharmaceutical batch(es) or pharmaceutical formulation(s) may have a maximum impurity level of Asp9-bivalirudin that does not exceed about 0.6%. Also, the pharmaceutical batch(es) or pharmaceutical formulation(s) may have a reconstitution time that does not exceed about 42 seconds. The method of preparing the pharmaceutical batch(es) or pharmaceutical formulation(s) may comprise dissolving bivalirudin in a solvent to form a first solution, efficiently mixing a pH-adjusting solution with the first solution to form a second solution in which the pH-adjusting solution may comprise a pH-adjusting solution solvent, and removing the solvent and the pH-adjusting solution solvent from the second solution.
摘要翻译：包含比伐卢定作为活性成分的药物批次或药物制剂以及制备药物批料或药物制剂的方法。药物批料或药物制剂可以具有不超过约0.6％的Asp9-比伐鲁丁的最大杂质水平。此外，药物批料或药物制剂可具有不超过约42秒的重构时间。制备药物批料或药物制剂的方法可以包括将比伐卢定溶解在溶剂中以形成第一溶液，有效地将pH调节溶液与第一溶液混合以形成第二溶液，其中pH- 调节溶液可以包含pH调节溶液溶剂，并从第二溶液中除去溶剂和pH调节溶液溶剂。

20. 发明申请

US20090226527A1 Particulate-stabilized injectable pharmacutical compositions of posaconazole 审中-公开
标题翻译：泊沙康唑的颗粒稳定的可注射药物组合物
公开(公告)号：US20090226527A1
公开(公告)日：2009-09-10
申请号：US12380790
申请日：2009-03-03
申请人： Leonore Witchey-Lakshmanan , Sydney Ugwu , Varda E. Sandweiss , Catherine Hardalo , Roberta S. Hare , Gopal Krishna , Zaiqi Wang , Marco Taglietti
发明人： Leonore Witchey-Lakshmanan , Sydney Ugwu , Varda E. Sandweiss , Catherine Hardalo , Roberta S. Hare , Gopal Krishna , Zaiqi Wang , Marco Taglietti
IPC分类号： A61K9/14 , A61P31/10
CPC分类号： A61K31/496 , A61K9/0019 , A61K31/137 , A61K31/513 , A61K31/7048 , A61K45/06 , A61K47/24 , A61K47/26 , Y02A50/409 , Y02A50/414 , A61K2300/00
摘要： The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient Posaconazole in an injectable suspension of particles that is stable when subjected to terminal sterilization. Preferred median particle sizes of between 1.5 and 3.0 microns are found to result in superior pharmacokinetic characteristics-displayed in FIG. 7.
摘要翻译：本发明提供了可用于治疗感染的制剂，特别是包含活性药物成分泊沙康唑在经受终末灭菌时稳定的颗粒的可注射悬浮液中的制剂。发现1.5至3.0微米的优选中值粒度导致优异的药代动力学特征 - 显示在图1中。 7。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式